Brexu-cel Results in High Rates of CNS Remission in R/R B-Cell ALL
It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.
SBRT Plus Standard of Care Improves PFS in Oligoprogressive NSCLC
Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.
Sacituzumab Govitecan Plus Pembrolizumab Improves Responses in Bladder Cancer
All prespecified patient subgroups with metastatic urothelial cancer showed a clinical benefit with sacituzumab govitecan plus pembrolizumab in cohort 3 of the phase 2 TROPHY-U-01 trial.
Tislelizumab Plus Chemo Improves Event-Free Survival in Stage II-IIIA NSCLC
The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.
Cabozantinib With Atezolizumab Significantly Improves PFS in Metastatic CRPC
Cabozantinib plus atezolizumab may be a new treatment option for patients with metastatic castration-resistant prostate cancer whose disease progressed on novel hormonal therapy.
Fruquintinib With Best Supportive Care Improves Survival, Quality of Life in Metastatic CRC
Fruquintinib showed potential in providing an improved quality of life and survival benefit in patients with previously treated metastatic colorectal cancer.
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.
mRNA Vaccine Continues to Show Promise in Resected Melanoma
Patients treated with mRNA-4157 plus pembrolizumab experienced an approximately 44% reduction in the risk of death or recurrence compared to those receiving pembrolizumab alone.
Lenvatinib/Pembrolizumab Elicits High, Durable Responses in Advanced RCC
Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.
Subgroup Analysis Shows Pembrolizumab Improves Outcomes in Clear Cell RCC
Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.
Bevacizumab-Based Regimen Improves PFS in HRD-Negative Advanced Ovarian Cancer
Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512